

Hanoi, January 19th, 2026

**EXPLANATION OF BUSINESS PERFORMANCE
FOR THE FOURTH QUARTER OF 2025**

Respectfully to: - State Securities Commission
- Hanoi Stock Exchange

Pursuant to:

- *Legal Regulations on Information Disclosure in the Securities Market;*
- *The self-prepared financial statements for Q4 2025 of Viet Nam Medicinal Materials Joint Stock Company;*

Viet Nam Medicinal Materials Joint Stock Company (Stock code: DVM) discloses information regarding the Q4/2025 Financial Statements, with the following results:

No.	Content	Q4 2025 (VND)	Q4 2024 (VND)	Difference	
				Value (VND)	%
1	Net revenue	422,954,245,160	406,894,080,821	16,060,164,339	3.95
2	Profit after tax	10,015,895,854	11,964,813,015	(1,948,917,161)	(16.29)

The company's profit after tax in the Q4/2025 financial statements decreased by approximately 16.29% compared to Q4/2024, primarily due to the following reasons:

- Although the revenue in Q4/2025 increased by VND 16,060,164,339 (equivalent to 3.95%) compared to Q4/2024, the cost of goods sold (COGS) also rose as the company prioritized clearing inventory.
- The financial expenses decreased due to a reduction in short-term loans.

- The above is Vietnam Medicinal Materials Joint Stock Company's explanation regarding the profit fluctuations in the Q4/2025 Financial Statements compared to the same period last year.

Recipients:

- GENERAL DIRECTOR**
- CÔNG TY
CỔ PHẦN
ĐƯỢC LIỆU
VIỆT NAM**
- TỈNH PHÚ THỌ**
- Vu Thanh Trung**

